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OBJECTIVE—We examined in 20-week-old Zucker diabetic
fatty (ZDF) rats whether restoration of hepatic glucokinase (GK)
expression would alter hepatic glucose ﬂux and improve hyper-
glycemia.
RESEARCH DESIGN AND METHODS—ZDF rats were
treated at various doses with an adenovirus that directs the
expression of rat liver GK (AdvCMV-GKL) dose dependently, and
various metabolic parameters were compared with those of
nondiabetic lean littermates (ZCL rats) before and during a
hyperglycemic clamp. Viral infection per se did not affect hepatic
GK activity, since expression of a catalytically inactive form of
GK did not alter endogenous hepatic GK activity.
RESULTS—ZDF rats compared with ZCL rats have lower he-
patic GK activity (11.6  1.9 vs. 32.5  3.2 mU/mg protein),
marked hyperglycemia (23.9  1.2 vs. 7.4  0.3 mmol/l), higher
endogenous glucose production (80  3 vs. 38  3 mol  kg
1 
min
1), increased glucose-6-phosphatase ﬂux (150  11 vs. 58 
8 mol  kg
1  min
1), and during a hyperglycemic clamp, a
failure to suppress endogenous glucose production (80  7 vs.
7  4 mol  kg
1  min
1) and promote glucose incorporation
into glycogen (15  5 vs. 43  3 mol/g liver). Treatment of ZDF
rats with different doses of AdvCMV-GKL, which restored hepatic
GK activity to one to two times that of ZCL rats, normalized
plasma glucose levels and endogenous glucose production. Dur-
ing a hyperglycemic clamp, glucose production was suppressed
and glucose incorporation into glycogen was normal.
CONCLUSIONS—Alteration of hepatic GK activity in ZDF rats
has profound effects on plasma glucose and hepatic glucose ﬂux.
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n Western society, obesity is generally considered a
primary risk for individuals with type 2 diabetes,
since 60–90% of type 2 diabetic subjects are also
obese (1). Initially, obese individuals have normal
fasting glycemia with elevated plasma insulin, but become
progressively more hyperglycemic and insulin resistant
with a decline in plasma insulin levels associated with
pancreatic -cell dysfunction (2). Diabetic hyperglycemia
results from a failure of insulin and elevated plasma
glucose to increase glucose utilization and suppress
endogenous glucose production (2). With 90% of en-
dogenous glucose production derived from liver (3,4)
and as much as 40% of alimentary glucose taken up by
liver (5–7), for storage as glycogen (8–10), a progressive
loss in these liver functions is associated with the
deterioration of glycemic control and the eventual de-
velopment of diabetes.
Whether liver uses or produces glucose is mostly deter-
mined by the activity of the ﬁrst and last enzymes of
hepatic glucose utilization and production, respectively.
Net hepatic glucose ﬂux is therefore the balance between
the rate of glucose phosphorylation catalyzed by glucoki-
nase (GK), the ﬁrst step of hepatic glucose utilization, and
the rate of glucose-6-phosphate (G-6-P) dephosphorylation
catalyzed by glucose-6-phosphatase (G-6-Pase), the last
step of hepatic glucose production. In studies of nondia-
betic rats, glucose-induced suppression of net hepatic
glucose production was associated with increased glucose
phosphorylation (11) and GK activity was required for a
rise in plasma glucose to suppress hepatic glucose produc-
tion (12).
Male Zucker diabetic fatty (ZDF) rats are a widely used
genetic model of obese type 2 diabetes, since many
characteristic features of this model are common with
human obese type 2 diabetes (13). Young ZDF rats exhibit
normal fasting glycemia with slightly elevated plasma
insulin levels and become progressively more hyperglyce-
mic and insulin resistant as plasma insulin levels are
decreased with pancreatic -cell dysfunction (14). Previ-
ously, we reported that blunted hepatic glucose ﬂux in
response to a rise in plasma glucose and insulin, as seen in
the early (10 weeks of age) and middle (14 weeks of age)
phases of diabetes development in ZDF rats, is associated
with impaired regulation of GK by GK regulatory protein
(GKRP) (15–17). In our current study, we investigated GK
expression in liver during the progressive development of
diabetes in ZDF rats and examined what correlation
altered GK expression may have with the development of
defective hepatic glucose metabolism and hyperglycemia.
We report here that GK expression in liver is progressively
reduced with the development of hyperglycemia in ZDF
rats and that normalizing liver GK expression restores
plasma glucose to nearly normal levels by improving the
responsiveness of hepatic glucose metabolism to alter-
ations in blood glucose during this later phase of diabetes
development in ZDF rats.
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Animal and surgical procedures. Six-week-old male ZDF (ZDF/GmiCrl-fa/
fa) rats and their lean littermates (ZDF/GmiCrl-/fa) were purchased from
Charles River Laboratories (Wilmington, MA) and were fed Formulab Diet
5008 (Purina Lab Diet; Purina Mills, Richmond, IN) in an environmentally
controlled room with a 12-h light/dark cycle. In one group of studies, rats 7, 10,
14, or 20 weeks of age were fasted for 6 h (from 7:00 A.M. to 1:00 P.M.) and then
anesthetized with sodium pentobarbital (60 mg/kg i.p.), and a laparotomy was
performed. Blood samples were collected from the inferior mesenteric artery,
and then the left lobe of the liver was frozen in situ using Wollenberg tongs
precooled in liquid nitrogen. These sampling procedures took 20 s from the
point of successful anesthesia. In a second group of studies, surgery was
performed to place sterile silicon rubber catheters in the ileal vein, the left
common carotid artery, and the right external jugular vein at 17 weeks of age
followed by a 2-week recovery period, as previously described (15,16,18). At
19 weeks of age, all animals received 15 mg/kg cyclosporine A via intraperi-
toneal injection the day before and on the day of adenovirus administration.
Recombinant adenoviruses that contain a cDNA encoding rat liver GK
(AdvCMV-GKL) or encoding a catalytically inactive mutant of GK (AdvCMV-
mutGK) were prepared as described previously (19,20) and administered into
the hepatic portal vein via the ileal vein catheter at doses of 0.5  10
11 (n 	
4), 1  10
11 (n 	 5), or 2  10
11 (n 	 5) particles for AdvCMV-GKL and at 2 
10
11 particles for AdvCMV-mutGK (n 	 4) or PBS (n 	 4) in a ﬁnal volume of
500 l PBS. All experiments were conducted in accordance with the Guide for
the Care and Use of Laboratory Animals of both the U.S. Department of
Agriculture and the National Institutes of Health, with all protocols receiving
approval from the Vanderbilt University Institutional Animal Care and Use
Committee.
Experimental design of hyperglycemic clamp studies. On the sixth day of
the treatment with virus or vehicle, the rats were fasted for 6 h before each
study, which consisted of a 2-h tracer equilibration period (180 to 60 min),
a 1-h basal period (60 to 0 min), and a 3-h test period (0–180 min). At 180
min, a 60-Ci bolus of [2-
3H]- and [3-
3H]glucose was given through the jugular
vein catheter and then infused continuously at 0.6 Ci/min. During the test
period, the plasma glucose levels were kept at 400 mg/dl by infusing a 50%
glucose solution into the systemic circulation through the jugular vein
catheter at a variable rate. Blood samples were taken from the arterial
catheter. Blood glucose levels were monitored using an Accu-Chek glucom-
eter (Roche Diagnostics, Indianapolis, IN). At each sampling time, erythro-
cytes were resuspended in saline and given back to the test animal during the
study. At the end of the experiment, the animal was anesthetized with an
intravenous infusion of sodium pentobarbital (40 mg/kg) and a laparotomy
was immediately performed. The left lobe of the liver was frozen in situ using
Wollenberg tongs precooled in liquid nitrogen. This procedure took 20 s
from the point of successful anesthesia.
Western blot analysis for GK and GKRP. Western blot analyses of GK and
GKRP were performed with anti-rat GST-GK and GST-GKRP sera (15,16).
Metabolites in blood and tissue. Glycogen and G-6-P content in liver,
plasma glucose, plasma free fatty acids (FFAs), plasma triglyceride, plasma
insulin, plasma glucagon, blood lactate, and blood alanine were determined as
previously described (15,16). [2-
3H]- and [3-
3H]glucose levels in plasma
glucose and liver glycogen were determined by selective enzymatic detritia-
tion of [2-
3H]glucose (16). External standards of [2-
3H]- and [3-
3H]glucose
suspended in control rat plasma were processed in parallel with each assay to
calculate the degree of detritiation of each isotope during each sample assay.
Overall completion of detritiation of [2-
3H]glucose was 97.2  0.4%, while
99.8  0.3% of [3-
3H]glucose remained intact. The speciﬁc activity of [2-
3H]-
and [3-
3H]glucose (dpm/mol) in plasma glucose was determined by the
method of Debodo et al. (21).
Enzyme activities. For GK and G-6-Pase activity measurements, 200 mg
freeze-clamped livers were homogenized in 2 ml buffer containing 50 mmol/l
HEPES, 100 mmol/l KCl, 1 mmol/l EDTA, 5 mmol/l MgCl2, and 2.5 mmol/l
dithioerythritol (22). Homogenates were centrifuged at 100,000g for 45 min to
sediment the microsomal fraction. GK and G-6-Pase activities were assayed in
the postmicrosomal and the microsomal fractions, respectively, as described
previously (16). Glycogen synthase and phosphorylase activities in the liver
were measured using the method described by Golden et al. (23).
Calculations. Rates of [2-
3H]- and [3-
3H]glucose–determined glucose turn-
over were calculated as the ratio of the rate of infusion of [2-
3H]- and
[3-
3H]glucose (dpm  kg
1  min
1) and the [2-
3H]- and [3-
3H] speciﬁc activity
in plasma glucose, respectively, according to the steady-state equations of
Steele et al. (24). Rate of endogenous glucose production was determined as
the difference between [3-
3H]glucose turnover rate and the glucose infusion
rate. To estimate the amount of glucose incorporated into hepatic glycogen via
the direct pathway, [3-
3H] incorporated into glycogen was divided by the
plasma glucose [3-
3H] speciﬁc activity, respectively. Glucose cycling is deﬁned
as input of extracellular glucose into the G-6-P pool followed by the return of
plasma glucose–derived G-6-P back into the extracellular pool; therefore,
glucose cycling rate was calculated as the difference between [2-
3H]glucose
turnover rate and [3-
3H]glucose turnover rate. The in vivo ﬂux through
G-6-Pase was calculated as the sum of endogenous glucose production plus
glucose cycling.
Statistical analysis. The data collected are expressed as means  SE. The
signiﬁcance of the differences between groups was analyzed by Student’s t
test. Differences were considered signiﬁcant when P  0.05.
RESULTS
Progression of diabetes and changes in hepatic GK
protein and activity along with aging in ZDF rats. As
the ZCL rats aged, their BMI tended to increase along with
an increase in body weight (Fig. 1A and B). While plasma
insulin and glucagon decreased and increased, respec-
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FIG. 1. Progressive changes in body weight (A), BMI (B), plasma insulin (C), plasma glucagon (D), plasma glucose (E), hepatic GK activity (F),
hepatic GK protein (G), and hepatic GKRP protein (H) with aging in ZDF rats and ZCL rats. Rats were fasted from 6:00 A.M. for 6 h before
sampling. Hepatic GK and GKRP protein are described as a ratio to that of a liver standard. f, ZDF rats. , ZCL rats. *P < 0.05 vs. lean littermates
of the same age, with each group having ﬁve animals.
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DIABETES, VOL. 58, JANUARY 2009 79tively (Fig. 1C and D), plasma glucose levels remained the
same at all four age-groups (Fig. 1E). In liver, protein
levels of GK and GKRP (Fig. 1G and H) as well as GK
activity (Fig. 1F) did not change. When these parameters
were measured in ZDF rats and compared with those of
ZCL rats, body weight, BMI, plasma insulin, plasma gluca-
gon, and hepatic GK protein and activity were higher at 7
weeks of age, whereas plasma glucose and GKRP protein
levels were similar (Fig. 1). At 10 weeks of age, plasma
glucose increased as hepatic GK activity declined (Fig. 1E
and F). After 10 weeks of age, plasma insulin and hepatic
GK protein and activity progressively decreased as plasma
glucose levels rose.
Effect of the treatment with AdvCMV-mutGK on
hepatic GK activity and metabolic proﬁles. Hepatic
GK activity, metabolic proﬁles (plasma levels of glucose,
insulin, glucagon, lipid, and gluconeogenic precursors),
and hepatic glucose ﬂuxes (glucose turnover, glucose
cycling, endogenous glucose production, and G-6-Pase
ﬂux) in 20-week-old ZDF rats treated with AdvCMV-
mutGK were similar to that of ZDF rats treated with
vehicle, indicating that viral infection per se and expres-
sion of a catalytically inactive form of GK protein did not
affect hepatic GK activity and metabolism.
Effect of the treatment with AdvCMV-GKL on hepatic
GK activity, plasma glucose, and body weight. Treat-
ment of ZDF rats with AdvCMV-GKL increased GK activity
dose-dependently (Fig. 2A). When ZDF rats were treated
with AdvCMV-GKL at 1 or 2  10
11 pfu, blood glucose
levels gradually fell over a 4-day period and remained at
this reduced level until the study was terminated on day 6
(Fig. 2B). Body weight was not altered by this increased
GK activity in liver (Fig. 2C and D).
Metabolite proﬁle of 20-week-old ZDF rats treated
with AdvCMV-GKL before and during a hyperglyce-
mic clamp. Figures 3 and 4 show a relationship between
measured metabolic parameters and hepatic GK activity,
as indicated by a smooth trend line for parameters mea-
sured before and during the clamp, respectively. The
normal level of GK expression in a nondiabetic liver was
determined by measuring GK activity in ZCL rats that
underwent the same hyperglycemic clamp. The activity
was determined to be 32.5  3.2 mU/mg total protein (the
activity range was from 28 to 40 mU/mg). ZDF rats treated
with AdvCMV-GKL were divided into three groups for
analytical comparison based on the level of hepatic GK
activity (ZDF-L, lower than normal range, 4–18 mU/mg;
ZDF-N, normal range, 21–55 mU/mg; ZDF-H, higher than
normal range, 64–91 mU/mg) as determined at the end of
the hyperglycemic clamp, and these groups were com-
pared with a group of ZCL rats that also underwent the
same hyperglycemic clamp. Table 1 shows the summary of
the metabolic proﬁles of these four groups of rats and
statistical analyses of these metabolic parameters. Before
a hyperglycemic clamp, compared with ZCL rats, ZDF-L
rats had similar plasma insulin and glucagon levels and
similar blood alanine levels. Plasma FFA level tends to be
higher. Blood lactate and plasma triglyceride levels were
much higher. Plasma glucose levels, [2-
3H]glucose turn-
over rates (which represent G-6-Pase ﬂux), [3-
3H]glucose
turnover rates, and glucose cycling rates were much
higher. Plasma glucose levels were reduced and reached
near-normal levels as hepatic GK activity approached that
of ZCL rats, and the restoration of nearly normal plasma
glucose levels were associated with decreased [2-
3H]- and
[3-
3H]glucose turnover. Additionally, a further increase in
GK activity to about twice that found in ZCL livers did not
further decrease plasma glucose levels, but instead,
tended to increase [2-
3H]- and [3-
3H]glucose turnover.
While blood lactate levels were slightly increased, blood
alanine levels, plasma insulin, plasma glucagon, and
plasma triglycerides did not change.
In ZCL rats during a hyperglycemic clamp, when plasma
glucose, insulin, and glucagon levels were raised to that
seen in ZDF-L rats, levels of blood lactate, but not blood
alanine and plasma triglyceride, tended to rise to that seen
in ZDF rats. Glucose turnover rates were increased three-
fold, and endogenous glucose production was completely
suppressed. Glucose cycling rates were also markedly
increased, and G-6-Pase ﬂux was not changed signiﬁcantly.
During a hyperglycemic clamp in ZDF-L rats, measured
parameters were not changed from that of the basal
period. In ZDF rats treated with AdvCMV-GKL, in parallel
with increased GK activity in the liver, plasma insulin and
glucagon were not changed from basal levels during the
glucose clamp. Blood lactate, but not blood alanine and
plasma triglyceride, levels were raised. Glucose turnover
rates and glucose cycling rates increased. Additionally,
endogenous glucose production was reduced with a de-
crease in G-6-Pase ﬂux.
At the end of the clamp period, as compared with ZCL
rats, in ZDF-L rats, G-6-P content (Fig. 5A) was signiﬁ-
cantly lower and the amount of incorporated glucose into
glycogen via the direct pathway was greatly reduced (Fig.
5C). Glycogen phosphorylase a activity was signiﬁcantly
higher, and in contrast, glycogen synthase I activity was
signiﬁcantly lower (Fig. 5D–F). In ZDF rats treated with
AdvCMV-GKL, in parallel with increased GK activity, G-6-P
content, glycogen content, and the amount of glucose
incorporated into glycogen via the direct pathway were
increased (Fig. 5 and Table 1). Total activity of glycogen
synthase was not changed, but the active form of glycogen
synthase was increased. Phosphorylase a activity was not
g
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pyruvate carboxykinase protein expression (data not
shown) were not signiﬁcantly different between ZCL and
ZDF rats without AdvCMV-GKL treatment and were not
changed with increased GK expression in ZDF rats.
DISCUSSION
Hepatic GK activity is decreased progressively with the
development of hyperglycemia in ZDF rats, so that by 20
weeks of age, activity is only 30% of that found in
nondiabetic ZCL rats. We demonstrated that normalization
of hepatic GK activity in 20-week-old ZDF rats improves
hepatic glucose ﬂux at basal as well as when presented
with a hyperglycemic challenge. The improved hepatic
glucose ﬂux restores blood glucose to normal levels. This
demonstrates that altered hepatic glucose metabolism,
responsible for hyperglycemia at this late stage of diabetes
in this animal model, at least partly, resulted from de-
creased GK activity.
Hepatic GK expression decreases progressively dur-
ing the development of diabetes in ZDF rats. An
increase in GK activity in liver has been described in obese
human subjects (25), obese hyperinsulinemic Zucker rats
(26), and young obese ob/ob mice (27). In coincidence with
these reports, ZDF rats have higher hepatic GK expression
at 7 weeks of age when they are obese with euglycemia
and hyperinsulinemia. GK expression then decreases pro-
gressively along with a progressive development of fasting
hyperglycemia and a corresponding reduction of plasma
insulin levels. It is known that expression of GK in the liver
is regulated by insulin through phosphatidylinositol 3-ki-
nase activation of a PKB/Akt-dependent signal (28). It was
reported that the activation of PKB/Akt by phosphatidyl-
inositol 3-kinase is impaired in the liver of ZDF rats (29).
Therefore, a progressive decrease of GK expression during
the development of diabetes may result from the presence
of hepatic insulin resistance that becomes more evident
when plasma insulin levels fall.
A role of GKRP in the regulation of not only GK activity
but also protein levels in the liver may be an alternative
explanation for the loss of GK activity with the progres-
sion of diabetes. In mice that do not express GKRP (GKRP
gene ablated), GK resides in the cytoplasm, and its expres-
sion is decreased by 50% without a decrease in mRNA
levels, which occurs despite the presence of normal
plasma insulin and glucose levels (30,31). In mice that
express a mutant form of GK, which is localized to the
cytoplasm and unable to bind GKRP, when compared with
wild-type mice, it was found that expression of this GK
was markedly lower despite being similar to wild-type
levels of GK mRNA (32). Additionally, degradation of GK
in cultured hepatocytes is decreased by increased GKRP
expression (33). In ZDF rats, GK is predominantly local-
ized in the nucleus with GKRP at an early stage of diabetes
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a time when GK expression remains at normal levels
(15,17). However, at around 14 weeks of age, GK expres-
sion is markedly reduced, and GK is predominantly local-
ized to the cytoplasm with the abnormal residency of
GKRP in the cytoplasm (16). These data suggest the
possibility that the inappropriate localization of GK in the
cytoplasm may increase GK degradation and thus eventu-
ally result and/or contribute to lower GK levels.
Restoration of hepatic glucose ﬂux responsiveness to
changes in plasma glucose by normalization of he-
patic GK expression. Net hepatic glucose ﬂux is the
balance between glucose utilization as initiated by glucose
phosphorylation to form G-6-P mediated by GK and glu-
cose production as concluded by G-6-P dephosphorylation
mediated by G-6-Pase. Therefore, a relative decrease in
G-6-Pase ﬂux and/or a relative increase in GK ﬂux would
lead to the observed decrease of net hepatic glucose
production. The lack of suppression of endogenous glu-
cose production in response to a hyperglycemic challenge
in ZDF rats was associated with lower G-6-P content and
glycogenesis via the direct pathway, suggesting lower
glucose phosphorylation by GK. Normalization of GK
expression restored suppression of endogenous glucose
production in response to a rise in plasma glucose levels.
The restoration was associated with restored glucose
phosphorylation by GK, since hepatic G-6-P content, glu-
cose cycling rate, and incorporation of glucose into glyco-
gen via the direct pathway all increased. The restoration of
glycogen synthesis by the direct pathway in response to a
rise of plasma glucose was associated with a restored
activation of glycogen synthase. It has been reported that
increases in G-6-P through mass action and its allosteric
regulatory effect on downstream enzymes in hepatocytes
plays a major role in mediating the effects of GK overex-
pression on hepatic glucose metabolism, glycogen synthe-
sis, and glycolysis (34).
Hepatic glucose production is predominantly via
gluconeogenesis in ZDF rats (16). The rate of gluconeo-
genesis is controlled principally by the activities of several
key enzymes, including G-6-Pase, fructose-1,6-bisphos-
phatase, and PEPCK. Increased G-6-Pase ﬂux was ob-
served in the liver of ZDF rats compared with ZCL rats.
Interestingly, there was a signiﬁcant decrease in G-6-Pase
ﬂux in parallel with normalized GK activity before and
during a hyperglycemic clamp (Table 1). Under a hyper-
glycemic clamp, decreased G-6-Pase ﬂux was observed
despite increased content of G-6-P, a substrate of G-6-
Pase, which suggests G-6-Pase activity was decreased.
However, the Vmax and apparent Km of G-6-Pase activity,
as measured in microsomal fractions of liver homogenates
from ZDF rats, were not different from that of ZCL rats,
and we detected no change in kinetic parameters after
altering GK expression. Minassian et al. (35) reported a
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short period of refeeding nondiabetic rats, as measured
from homogenates of livers freeze-clamped in situ but not
in the microsomal fractions isolated from these liver
homogenates, which may suggest that an inhibitor that is
either highly labile or that is lost during the process of
microsome isolation (35). During the last decade, several
intermediates of metabolism, such as free fatty acids,
acyl-CoA, 
-ketoglutarate (36,37), and lipid products of
phosphatidylinositol 3-kinase (38) have been reported to
alter G-6-Pase activity allosterically. In a future study, we
hope to identify what intracellular factor(s) may mediate
the decreased G-6-Pase activity that is associated with the
restoration of GK expression.
Relationship between increased glucose cycling and
GK expression. ZDF rats have an increased rate of an
apparent futile cycle of glucose to G-6-P and back to
glucose that is a characteristic of insulin resistance and
hyperglycemia seen with type 2 diabetes (39–41). This
increased glucose cycling appears to be associated with
increased rates of phosphorylation of glucose and/or de-
phosphorylation of G-6-P. Increased glucose phosphoryla-
tion increases the intracellular concentration of G-6-P and
the fractional contribution of plasma glucose to this G-6-P
pool. This also leads to an increased dephosphorylation of
G-6-P derived from plasma glucose by increasing total
G-6-Pase ﬂux and/or the fraction of G-6-P derived from
plasma glucose in the total G-6-P dephosphorylated by
G-6-Pase (the later could occur even without an increase
in total G-6-Pase ﬂux).
It is unlikely that increased glucose cycling in ZDF rats
is associated with only altered GK expression. Compared
with ZCL rats, glucose cycling under a basal condition is
threefold higher at an early stage of diabetes in ZDF rats
(10 weeks of age), when these ZDF rats have similar GK
expression, but do have lower GK activity due to a
defective activation of the enzyme by glucose via an
apparent failure of GK to dissociate from its inhibitory
protein (GKRP) (15,17). Glucose cycling is increased fur-
ther during the progression of diabetes in ZDF rats, as is
found at 20 weeks of age when GK expression is decreased
(Table 1) (15,16). However, the restoration and increase of
GK expression at this phase of diabetes in ZDF rats did not
affect glucose cycling. These ﬁndings suggest that other
factors, other than lower GK activity, is involved in the
increased glucose cycling associated with diabetes.
Maintenance of GK expression in liver as a possible
gene therapy–based approach for reducing hypergly-
cemia in type 2 diabetes. O’Doherty et al. (42) reported
that lowering of blood glucose and plasma insulin by a
sixfold increase in hepatic GK expression in nondiabetic
rats using an adenovirus were accompanied by marked
increases in plasma triglycerides, FFAs, cholesterol, -hy-
droxybutylate, and lactate. Our study shows that increase
in hepatic GK expression above normal tended to worsen
hyperlipidemia and hyperlactemia in ZDF rats, a model of
type 2 diabetes associated with obesity. We previously
reported that 90% of hepatic glucose production in ZDF
rats is due to gluconeogenesis (16). Since elevated GK
expression decreased endogenous glucose production un-
der basal conditions and during hyperglycemic clamp, it is
probable that the observed increase in blood lactate levels
associated with greater GK expression resulted from an
inhibition of gluconeogenesis. Increased glycolytic ﬂux
and/or decreased gluconeogenic ﬂux, as a consequence of
GK overexpression, would likely increase the concentra-
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tion of triglyceride. Furthermore, excessively increased
G-6-P concentration would stimulate expression of the
fatty acid synthase gene via activation through its carbo-
hydrate response element (43,44). Therefore, an excessive
induction of hepatic GK expression might have a risk to
generate or worsen complications associated with type 2
diabetes.
On the other hand, O’Doherty et al. (42) also reported
that a mild (threefold) increase in hepatic GK expression
in nondiabetic rats did not alter the basal metabolic
proﬁle. Transgenic mice overexpressing GK exhibited a
slight decrease in blood glucose levels and no alteration of
plasma lipid levels (45). These observations suggested a
less impact of mildly increased hepatic GK expression on
basal glycemia and lipidemia in normal animals. Neverthe-
less, transgenic mice expressing GK at approximately
twofold of that in the wild-type mice are more tolerant to
glucose challenge (45), more tolerant of streptozotocin-
induced diabetes (46), and more resistant to high-fat
diet–induced diabetes (47,48). These beneﬁts are not ac-
companied by altering plasma lactate, FFAs, and triglyc-
erides (46–48). Our present study shows in 20-week-old
ZDF rats that a short-term normalization of GK expression
in liver improves hepatic glucose ﬂux and restores blood
glucose levels to near normal, even at the late stage of
diabetes where plasma glucose levels are 25 mmol/l and
compensatory hyperinsulinemia does not exist anymore. It
has been recently reported that single-dose administration
of GK activator lowers fasting and postglucose–chal-
lenged plasma glucose levels by declining endogenous
glucose production, in addition to by improving glucose
utilization in patient with type 2 diabetes (49). These
results clearly suggest that maintenance of near-normal
GK activity in the liver, either by a gene therapy–based
approach or possibly by pharmaceutical intervention, is a
likely therapeutic target for the restoration of normogly-
cemia in type 2 diabetes.
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